RLAY
Relay Therapeutics Inc.
$7.14
-$0.20(-2.72%)
56
Overall
60
Value
66
Tech
44
Quality
Market Cap
$803.44M
Volume
1.45M
52W Range
$1.78 - $7.64
Target Price
$13.60
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | $82.7M | $3.0M | $1.4M | $25.5M | $10.0M | ||
| Total Revenue | $82.7M | $3.0M | $1.4M | $25.5M | $10.0M | ||
| GROSS PROFIT | |||||||
| Gross Profit | $82.7M | $3.0M | $1.4M | $25.5M | $10.0M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $138.4M | $367.7M | $312.3M | $398.5M | $382.5M | ||
| Research & Development | $99.9M | $295.6M | $246.4M | $330.0M | $319.1M | ||
| Research Expense | $99.9M | $295.6M | $246.4M | $330.0M | $319.1M | ||
| Selling, General & Administrative | $38.6M | $57.4M | $66.0M | $75.0M | $76.6M | ||
| General & Administrative Expenses | $38.6M | $57.4M | $66.0M | $75.0M | $76.6M | ||
| Salaries & Wages | -- | -- | -- | $86.0M | $94.1M | ||
| Depreciation & Amortization | $3.5M | $3.9M | $4.1M | $5.3M | $5.5M | ||
| Depreciation & Amortization | $3.5M | $3.9M | $4.1M | $5.3M | $5.5M | ||
| Other Operating Expenses | $4.0M | -- | $11.7M | $398.5M | $382.5M | ||
| OPERATING INCOME | |||||||
| Operating income | $-55.8M | $-364.7M | $-299.3M | $-373.0M | $-372.5M | ||
| EBITDA | $-52.2M | $-223.1M | $-306.8M | $-336.7M | $-332.2M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | -- | $11.9M | -- | -- | -- | ||
| Intinc | $3.4M | $830.0K | $8.8M | $31.0M | $34.7M | ||
| Net Non-Operating Interest Income/Expense | $3.4M | $-11.0M | $8.8M | $31.0M | $34.7M | ||
| Other Income/Expense | $16.0K | $4.0M | $11.7M | $-41.3M | $-34.0M | ||
| Other Special Charges | $-16.0K | $-2.8M | $-20.0K | $31.0M | $34.8M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-55.8M | $-227.0M | $-311.0M | $-342.0M | $-337.7M | ||
| Pre-Tax Income | $-52.4M | $-361.0M | $-290.5M | $-348.4M | $-337.7M | ||
| NET INCOME | |||||||
| Net Income | $-52.4M | $-363.9M | $-290.5M | $-342.0M | $-337.7M | ||
| Net Income (Continuing Operations) | $-52.4M | $-363.9M | $-290.5M | $-342.0M | $-337.7M | ||
| Net Income (Discontinued Operations) | $-52.4M | $-363.9M | $-290.5M | $-342.0M | $-337.7M | ||
| Net Income (Common Stockholders) | $-230.2M | $-363.9M | $-290.5M | $-342.0M | $-337.7M | ||
| Normalized Income | -- | -- | -- | -- | $-347.4M | ||
| TOTALS | |||||||
| Total Expenses | $138.4M | $367.7M | $312.3M | $398.5M | $382.5M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $42.6M | $95.1M | $112.2M | $122.6M | $142.9M | ||
| Average Shares Outstanding (Diluted) | $42.6M | -- | $112.2M | $122.6M | $142.9M | ||
| Shares Outstanding | $90.4M | $108.3M | $121.4M | $131.2M | $169.5M | ||
| Basic EPS | $-5.4 | $-3.82 | $-2.59 | $-2.79 | $-2.36 | ||
| Basic EPS (Continuing Operations) | $-5.4 | $-3.82 | $-2.59 | $-2.79 | $-2.36 | ||
| Diluted EPS | $-5.4 | $-3.82 | $-2.59 | $-2.79 | $-2.36 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-2.59 | $-2.79 | $-2.36 | ||
| OTHER METRICS | |||||||
| Accrued Preferred Stock Dividends | $177.8M | -- | -- | -- | -- | ||
| Other Gand A | $38.6M | $57.4M | $66.0M | $75.0M | $76.6M | ||
| Otherunder Preferred Stock Dividend | $177.8M | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $177.8M | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RLAY | $7.14 | -2.7% | 1.45M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |